Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 61

1.

Cost Burden of Chronic Pain Patients in a Large Integrated Delivery System in the United States.

Park PW, Dryer RD, Hegeman-Dingle R, Mardekian J, Zlateva G, Wolff GG, Lamerato LE.

Pain Pract. 2015 Oct 7. doi: 10.1111/papr.12357. [Epub ahead of print]

PMID:
26443292
2.

Prevalence of Chronic Pain in a Large Integrated Healthcare Delivery System in the U.S.A.

Lamerato LE, Dryer RD, Wolff GG, Hegeman-Dingle R, Mardekian J, Park PW, Zlateva G.

Pain Pract. 2015 Jul 30. doi: 10.1111/papr.12334. [Epub ahead of print]

PMID:
26223221
3.

Delivery of size-controlled long-circulating polymersomes in solid tumours, visualized by quantum dots and optical imaging in vivo.

Bakalova R, Lazarova D, Nikolova B, Atanasova S, Zlateva G, Zhelev Z, Aoki I.

Biotechnol Biotechnol Equip. 2015 Jan 2;29(1):175-180. Epub 2014 Nov 26.

4.

The Comparative Burden of Chronic Widespread Pain and Fibromyalgia in the United States.

Schaefer C, Mann R, Masters ET, Cappelleri JC, Daniel SR, Zlateva G, McElroy HJ, Chandran AB, Adams EH, Assaf AR, McNett M, Mease P, Silverman S, Staud R.

Pain Pract. 2015 May 16. doi: 10.1111/papr.12302. [Epub ahead of print]

PMID:
25980433
5.

Health-resource use and costs associated with fibromyalgia in France, Germany, and the United States.

Knight T, Schaefer C, Chandran A, Zlateva G, Winkelmann A, Perrot S.

Clinicoecon Outcomes Res. 2013 Apr 23;5:171-80. doi: 10.2147/CEOR.S41111. Print 2013.

6.

Evaluation of the fibromyalgia impact questionnaire at baseline as a predictor for time to pain improvement in two clinical trials of pregabalin.

Bushmakin AG, Cappelleri JC, Chandran AB, Zlateva G.

Int J Clin Pract. 2013 Jan;67(1):52-9. doi: 10.1111/ijcp.12035.

PMID:
23241048
7.

Estimating the economic benefits of positive shifts in fibromyalgia severity: an exploratory analysis based on modeling of clinical trial data of pregabalin.

Cappelleri JC, Bushmakin AG, Zlateva G, Chandran A.

J Med Econ. 2013;16(1):55-61. doi: 10.3111/13696998.2012.727930. Epub 2012 Sep 17.

PMID:
22954060
8.

Simplifying Fibromyalgia Assessment: The VASFIQ Brief Symptom Scale.

Boomershine CS, Emir B, Wang Y, Zlateva G.

Ther Adv Musculoskelet Dis. 2011 Oct;3(5):215-26. doi: 10.1177/1759720X11416863.

9.
10.

Societal and individual burden of illness among fibromyalgia patients in France: association between disease severity and OMERACT core domains.

Perrot S, Schaefer C, Knight T, Hufstader M, Chandran AB, Zlateva G.

BMC Musculoskelet Disord. 2012 Feb 17;13:22. doi: 10.1186/1471-2474-13-22.

11.

The cost-effectiveness of pregabalin in the treatment of fibromyalgia: US perspective.

Lloyd A, Boomershine CS, Choy EH, Chandran A, Zlateva G.

J Med Econ. 2012;15(3):481-92. doi: 10.3111/13696998.2012.660254. Epub 2012 Feb 17. Review.

PMID:
22339078
12.

Clinical comorbidities, treatment patterns, and healthcare costs among patients with fibromyalgia newly prescribed pregabalin or duloxetine in usual care.

Gore M, Tai KS, Chandran A, Zlateva G, Leslie D.

J Med Econ. 2012;15(1):19-31. doi: 10.3111/13696998.2011.629262. Epub 2011 Oct 20.

PMID:
21970699
13.

Clinical characteristics, pharmacotherapy, and healthcare resource use among patients with fibromyalgia newly prescribed pregabalin or tricyclic antidepressants.

Gore M, Tai KS, Chandran A, Zlateva G, Leslie D.

J Med Econ. 2012;15(1):32-44. doi: 10.3111/13696998.2011.629263. Epub 2011 Oct 20.

PMID:
21970698
14.

The comparative burden of mild, moderate and severe fibromyalgia: results from a cross-sectional survey in the United States.

Schaefer C, Chandran A, Hufstader M, Baik R, McNett M, Goldenberg D, Gerwin R, Zlateva G.

Health Qual Life Outcomes. 2011 Aug 22;9:71. doi: 10.1186/1477-7525-9-71.

15.

Relationships between changes in pain severity and other patient-reported outcomes: an analysis in patients with posttraumatic peripheral neuropathic pain.

van Seventer R, Serpell M, Bach FW, Morlion B, Zlateva G, Bushmakin AG, Cappelleri JC, Nimour M.

Health Qual Life Outcomes. 2011 Mar 25;9:17. doi: 10.1186/1477-7525-9-17.

16.

Clinical characteristics, pharmacotherapy, and healthcare resource use among patients with diabetic neuropathy newly prescribed pregabalin or gabapentin.

Gore M, Tai KS, Zlateva G, Bala Chandran A, Leslie D.

Pain Pract. 2011 Nov-Dec;11(6):528-39. doi: 10.1111/j.1533-2500.2011.00450.x. Epub 2011 Mar 16.

PMID:
21435162
17.

Impact of fibromyalgia severity on health economic costs: results from a European cross-sectional study.

Winkelmann A, Perrot S, Schaefer C, Ryan K, Chandran A, Sadosky A, Zlateva G.

Appl Health Econ Health Policy. 2011 Mar 1;9(2):125-36. doi: 10.2165/11535250-000000000-00000.

PMID:
21332254
18.

Treatment patterns among physician specialties in the management of fibromyalgia: results of a cross-sectional study in the United States.

McNett M, Goldenberg D, Schaefer C, Hufstader M, Baik R, Chandran A, Zlateva G.

Curr Med Res Opin. 2011 Mar;27(3):673-83. doi: 10.1185/03007995.2011.553214. Epub 2011 Feb 7.

PMID:
21294700
19.

Correlations between fibromyalgia symptom and function domains and patient global impression of change: a pooled analysis of three randomized, placebo-controlled trials of pregabalin.

Arnold LM, Zlateva G, Sadosky A, Emir B, Whalen E.

Pain Med. 2011 Feb;12(2):260-7. doi: 10.1111/j.1526-4637.2010.01047.x. Epub 2011 Jan 25.

20.

Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis.

Chakravarthy U, Wong TY, Fletcher A, Piault E, Evans C, Zlateva G, Buggage R, Pleil A, Mitchell P.

BMC Ophthalmol. 2010 Dec 13;10:31. doi: 10.1186/1471-2415-10-31. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk